Article

barrons.com on 2021-01-13 14:56

Regeneron Inks Deal to Sell Covid-19 Treatment to U.S., Even as Usage Lags

One analyst estimates that the deal could add $1.6 billion to the biotech’s revenue. The deal gives the drug an effective price of $2,100 a dose.

Related news